FOR IMMEDIATE RELEASE

NEWS RELEASE

TSX Venture: **AMF**

AMORFIX LIFE SCIENCES IN-LICENSES SECOND NOVEL TECHNOLOGY TO STRENGTHEN ITS ALS THERAPEUTIC PROGRAM

TORONTO, ON, April 4, 2006 – Amorfix Life Sciences Ltd. reported today that it has obtained the exclusive worldwide rights to additional novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). These new SOD1 targets broaden Amorfix's intellectual property estate on SOD1 and enhance its existing diagnostic and therapeutic strategies for the treatment of ALS. The company also obtained an option to acquire the intellectual property and know how surrounding the licensed technology.

The novel SOD1 targets were discovered by Dr. Avi Chakrabarrty and Mr. Rishi Rakhit at the University Health Network (UHN) and Dr. Neil Cashman, the company's Chief Scientific Officer, in his former academic laboratory at the University of Toronto. Dr. Cashman has assigned his portion of the technology rights to Amorfix. The company has licensed the remaining rights from UHN and has committed to invest a minimum of $260,000 on development of the technology at UHN. Dr. Chakrabartty is a Senior Scientist at UHN Ontario Cancer Institute, Division of Biophysics and Bioimaging and an Associate Professor at the Departments of Biochemistry and Medical Biophysics at the University of Toronto. Dr. Chakrabartty has been collaborating with Dr. Cashman over the past several years to elucidate the mechanisms of protein misfolding in neurodegenerative diseases.

"I am very pleased my collaborators have chosen Amorfix to commercialize this invention and create an effective treatment for ALS", stated Dr. Cashman, who is also the Director of the ALS Centre at the Vancouver Coastal Health Authority.

This transaction is subject to acceptance for filing by the TSX Venture exchange.

About Amorfix

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up "prions," the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). Amorfix was formed to commercialize epitope protection (EP) technologies and related discoveries to become the world leader on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and preventative therapies for AMP diseases.

For further information, please contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-482-3812
info@amorfix.com

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-482-3814

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.